OBJECTIVES::  Oxycodone is a strong opioid absent from Brazilian federal guidelines (PCDT) for cancer pain treatment. According to literature, it is an effective option for opioid rotation for the control of pain in oncologic patients. The goal of this study is to calculate the budget-impact of the inclusion of oxycodone for cancer pain to the PCDT. METHODS::  SUS claim databases (DataSUS) reports the number of patients using each of the opioids available in Brazil, however it does not report dispensed opioids for all Brazilian states. To estimate the total number of patients with cancer pain using strong opioids, we selected patients using opioids during cancer treatment and extrapolated the number of patients based on the proportion of the population present in the states that report opioid consumption. Also based on DataSUS databases, mean treatment period was assumed to be 4.5 months. We assumed that the population growth would be the same as that of cancer incidence and that oxycodone’s market share at peak would be 25%, since in the literature 1/4 of the patients may not respond to morphine, reached within four years after protocol inclusion. Only drug costs were considered and time horizon is five years. One-way sensitivity analysis was performed in order to test which parameters most affect the result of the analysis. RESULTS:: The estimated number of patients using strong opioids for cancer pain by the fifth year of the analysis is 16.350, of which 4.088 are expected to be using oxycodone. The calculated impact is BRL 18 million. The parameters that most affect the result of the analysis are: market share and average treatment period. However, the result is not expected to be significantly higher than estimated in the base case analysis. CONCLUSIONS:: According to published literature, oxycodone´s inclusion impact on PCDT is considered medium.